Pfizer (PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.66 +0.07%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.6%
Join SI Premium – FREE
Pfizer (NYSE: PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lakewood-Amedex gets IRB approval for diabetic foot ulcer trial
- SmartKem (SMTK) files for 15.13M share offering by selling stockholders
- First Carolina Financial Services CFO to retire in January 2027
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
